Business
OWC Pharmaceutical Research Corp to Initiate Efficacy Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis
OWC Pharmaceutical Research Corp to Initiate Efficacy Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Research Corp to Initiate Efficacy Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis\n\n\n\n\n\nOWC Pharmaceutical Research Corp to Initiate Efficacy Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis\nCompany Anticipates Product Launch In Second Quarter 2017\nPR Newswire\nPETACH TIKVA, Israel, October 11, 2016\n\n\n\nPETACH TIKVA, Israel, October 11, 2016 /PRNewswire/ --\n\nOWC Pharmaceutical Research Corp. (OTCQB: OWCP), (\"OWC\" or the \"Company\"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it is starting the final phase for testing the efficacy of its own developed topical crème compound for the treatment of psoriasis and related skin conditions.\n\n     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )\n\n\n     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )\n\n\nThe Company's recently completed Challenge Testing for the topical crème, successfully demonstrated the product's robustness against microbiological contamination, stability, and provided a preliminary safety assessment. This next phase of Safety testing protocol was designed to corroborate that the cream is safe for application to the skin. This will be demonstrated by giving a highly concentrated topical crème formulation to healthy patients within a hospital controlled environment. The safety phase will start upon receiving the Institutional Review Board (IRB) approval by the national IRB committee which is expected to be assembled in November 2016.\n\nOWC is also preparing to initiate in parallel Efficacy Testing using MatTek Corporation patented EpiDerm™ system, an in-vitro testing technology for dermal toxicologists. This protocol will seek to prove the effectiveness of the formulation in treating psoriasis on human skin tissue. The tests will be conducted at an approved international lab of Dead Sea & Arava Science Center under the auspices of the Ben-Gurion University of the Negev (http://www.adssc.org/ ).\n\nDr. Yehuda Baruch, the Company's Director of Research and Regulatory Affairs, commented on the announcement, \"Psoriasis is an affliction of the immune system resulting in sub-dermal infection that can be ...